China cancer monoclonal antibodies market is estimated to grow at a CAGR of 11.6% during the forecast period. An increasing launch of biosimilars has been witnessed in the country owing to the increasing focus on providing affordable cancer therapy in the country. For instance, in August 2020, China’s NMPA (National Medical Products Administration) approved a biosimilar version of Roche’s Herceptin (trastuzumab), Shanghai’s Henlius which is referred to as HLX02 to treat HER2-mutated cancers. As its reference product, this biosimilar is also used for the treatment of HER2-positive early breast cancer, metastatic gastric cancer, and metastatic breast cancer. This therapy was demonstrated to be very similar to Roche’s Herceptin regarding safety, efficacy, and quality in preclinical, Phase 1, and Phase 3 studies. It is expected that this therapy will benefit HER2-positive gastric cancer and breast cancer patients in China.
To Request a Sample of our Report on China Cancer Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/china-cancer-monoclonal-antibodies-market
Further, in June 2020, Innovent Biologics, Inc. declared the NMPA approval of BYVASDA (bevacizumab biosimilar). It is a recombinant humanized anti-VEGF monoclonal antibody drug for patients suffering from advanced metastatic colorectal cancer and non-small cell lung cancer in China. NMPA has approved Innovent’s second monoclonal antibody drug, followed by TYVYT (sintilimab injection), which is approved to treat patients suffering from Hodgkin’s lymphoma in December 2018.
Scope of the China Cancer Monoclonal Antibodies Market
- Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and Application
- Competitive Landscape- AstraZeneca plc, Pfizer Inc., Innovent Biologics, Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Amgen Inc.
Recent Strategic Initiatives in the China Cancer Monoclonal Antibodies Market
- In December 2019, AstraZeneca declared that NMPA has granted marketing authorization for Imfinzi (durvalumab) to treat patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy (CRT). This approval represents the company’s long-standing commitment to improve the health outcomes of lung cancer patients in China.
- In October 2019, Amgen declared collaboration with BeiGene that will further widen Amgen’s plans to enhance its oncology presence in China. Under the agreement, BeiGene will commercialize BLINCYTO (blinatumomab), XGEVA (denosumab), and KYPROLIS (carfilzomib) in China. Additionally, this acquisition will also support Amgen for the commercialization of its non-oncology product portfolio in China.
(Get 15% Discount on Buying this Report)
A full Report of China Cancer Monoclonal Antibodies Market is Available at: https://www.omrglobal.com/industry-reports/china-cancer-monoclonal-antibodies-market
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in the base year?
- Which segment will project the fastest growth in the market?
- How COVID-19 impacted the market?
Ø Recovery Timeline
Ø Deviation from the pre-COVID forecast
Ø Most affected country/segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
China Cancer Monoclonal Antibodies Market-Segmentation
By Type
- Naked
- Conjugated
- Others (Bispecific)
By Application
- Breast Cancer
- Liver Cancer
- Blood Cancer
- Brain Cancer
- Colorectal Cancer
- Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
